Results 181 to 190 of about 9,424 (215)
Some of the next articles are maybe not open access.
Improved Glycemic Control in Mice Lacking Sglt1 and Sglt2
American Journal of Physiology - Endocrinology and Metabolism, 2013Sodium-glucose cotransporter 2 (SGLT2) is the major, and SGLT1 the minor, transporter responsible for renal glucose reabsorption. Increasing urinary glucose excretion (UGE) by selectively inhibiting SGLT2 improves glycemic control in diabetic patients. We generated Sglt1 and Sglt2 knockout (KO) mice, Sglt1/Sglt2 double-KO (DKO) mice, and wild-type (WT)
David R Powell +2 more
exaly +3 more sources
How Drugs Interact with Transporters: SGLT1 as a Model
Journal of Membrane Biology, 2008Drugs are transported by cotransporters with widely different turnover rates. We have examined the underlying mechanism using, as a model system, glucose and indican (indoxyl-beta-D-glucopyranoside) transport by human Na+/glucose cotransporter (hSGLT1).
Donald D F, Loo +3 more
openaire +2 more sources
Pflügers Archiv - European Journal of Physiology, 2014
Novel affinity-purified antibodies against human SGLT1 (hSGLT1) and SGLT2 (hSGLT2) were used to localize hSGLT2 in human kidney and hSGLT1 in human kidney, small intestine, liver, lung, and heart. The renal locations of both transporters largely resembled those in rats and mice; hSGLT2 and SGLT1 were localized to the brush border membrane (BBM) of ...
Vrhovac, Ivana +12 more
openaire +4 more sources
Novel affinity-purified antibodies against human SGLT1 (hSGLT1) and SGLT2 (hSGLT2) were used to localize hSGLT2 in human kidney and hSGLT1 in human kidney, small intestine, liver, lung, and heart. The renal locations of both transporters largely resembled those in rats and mice; hSGLT2 and SGLT1 were localized to the brush border membrane (BBM) of ...
Vrhovac, Ivana +12 more
openaire +4 more sources
Phenylglucosides and the Na+/glucose cotransporter (SGLT1): Analysis of interactions
The Journal of Membrane Biology, 1994Phenylglucosides are transported by the intestinal Na+/glucose cotransporter (SGLT1) and phlorizin, the classical competitive inhibitor of SGLT1, is also a phenylglucoside. To investigate the structural requirements for binding of substrates to SGLT1, we have studied the interactions between phenylglucosides and the cotransporter expressed in Xenopus ...
M P, Lostao +3 more
openaire +2 more sources
The Na+/glucose cotransporter (SGLT1).
Acta physiologica Scandinavica. Supplementum, 1992An important class of Na+ transport proteins is the cotransporters. They exist in bacteria and animal cells and are responsible for the "active" accumulation of sugars, amino acids, carboxylic acids and some ions, e.g., I-, Cl-, and PO-4, in cells.
E M, Wright +6 more
openaire +1 more source
Regulation of SGLT1 expression in response to Na+ intake
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2002In the chicken intestine, the reduction in Na+ intake led to a decrease in the transport of α-methyl-d-glucoside in the ileum (reduction of 42%) and in the rectum (51%). These reductions were reversed within 24 h after resalination and were inversely correlated to the changes in aldosterone plasma concentration.
Anna, Barfull +3 more
openaire +2 more sources
Sodium-Dependent Reorganization of the Sugar-Binding Site of SGLT1
Biochemistry, 2007The sodium-dependent glucose cotransporter SGLT1 undergoes a series of voltage- and ligand-induced conformational changes that underlie the cotransport mechanism. In this study we describe how the binding of external Na changes the conformation of the sugar-binding domain, exposing residues that are involved in sugar recognition to the external ...
Hirayama, Bruce A +7 more
openaire +3 more sources
2014
One of the diseases in humans, with most growing incidence, is diabetes mellitus type 2, which is characterized by hyperglycemia and various successive complications. Novel antidiabetic drugs have been proposed that would inhibit the activity of SGLT1 (SLC5A1 in humans)/Sglt1 (Slc5a1 in rodents) in the brush-border membrane (BBM) of small intestinal ...
Sabolić, Ivan +3 more
openaire +2 more sources
One of the diseases in humans, with most growing incidence, is diabetes mellitus type 2, which is characterized by hyperglycemia and various successive complications. Novel antidiabetic drugs have been proposed that would inhibit the activity of SGLT1 (SLC5A1 in humans)/Sglt1 (Slc5a1 in rodents) in the brush-border membrane (BBM) of small intestinal ...
Sabolić, Ivan +3 more
openaire +2 more sources
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes
Expert Review of Endocrinology & Metabolism, 2018Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. The agent blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1. Initial studies were directed at type 1 diabetes.
openaire +2 more sources